Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KDM6B | O15054 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079078 | 0.87 | DHODH (0.53) | MYCDHODHKDM4CKDM5AKDM5B | |
| SCHEMBL6637548 | 0.87 | SIRT3 (0.50) | MYCTACR1DHODHKDM4CKDM5A | |
| SCHEMBL20593569 | 0.86 | KDM4C (0.53) | MYCKDM4CKDM5BKDM4DKDM4E | |
| SCHEMBL27821329 | 0.85 | SIRT3 (0.57) | TACR1KDM4ETDP1GPBAR1 | |
| SCHEMBL27967304 | 0.83 | MYC (0.53) | MYCDHODHKDM4CKDM5AKDM5B | |
| SCHEMBL21056662 | 0.83 | KDM4E (0.54) | TACR1KDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6862976 | 0.83 | TACR1 (0.47) | TACR1KDM4CALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL2560322 | 0.82 | KDM4C (0.49) | MYCKDM4CKDM4DKDM4EKDM6B | |
| Hydrochloric Acid SCHEMBL14861781 | 0.82 | MYC (0.51) | MYCDHODHKDM4CKDM5AKDM5B | |
| SCHEMBL30782804 | 0.81 | KDM4C (0.49) | DHODHKDM4CKDM5BKDM4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-112105354-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| EP-1157005-B1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1157005-A1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-28 | — | — | EP | disclosed |
| US-6277871-B1 | ANTICANCER AGENTS | ABBOTT LABORATORIES | 2001-08-21 | — | — | US | disclosed |
| US-6225316-B1 | GOOD AFFINITY TO THE NK-1 RECEPTOR. | HOFFMANN-LA ROCHE INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2000050401-A1 | 3-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | MYC 127/4885TACR1 4350/4885DHODH 3323/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | MYC 127/4885TACR1 4350/4885DHODH 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.